These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 20225329)
1. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703 [TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. Yoshimura A; Noro R; Miyanaga A; Mizutani H; Kosaihira S; Minegishi Y; Seike M; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Gemma A; Anticancer Res; 2012 Oct; 32(10):4473-8. PubMed ID: 23060575 [TBL] [Abstract][Full Text] [Related]
4. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870 [TBL] [Abstract][Full Text] [Related]
5. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503 [TBL] [Abstract][Full Text] [Related]
7. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T; Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M; J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657 [TBL] [Abstract][Full Text] [Related]
9. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR; Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808 [TBL] [Abstract][Full Text] [Related]
12. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543 [TBL] [Abstract][Full Text] [Related]
13. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727 [TBL] [Abstract][Full Text] [Related]
15. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T; Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370 [TBL] [Abstract][Full Text] [Related]
16. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer. Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753 [TBL] [Abstract][Full Text] [Related]
18. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. Noro R; Yoshimura A; Yamamoto K; Miyanaga A; Mizutani H; Minegishi Y; Seike M; Kubota K; Kosaihira S; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Uematsu K; Gemma A; Anticancer Res; 2013 Mar; 33(3):1117-23. PubMed ID: 23482789 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. Glisson BS; Kurie JM; Perez-Soler R; Fox NJ; Murphy WK; Fossella FV; Lee JS; Ross MB; Nyberg DA; Pisters KM; Shin DM; Hong WK J Clin Oncol; 1999 Aug; 17(8):2309-15. PubMed ID: 10561292 [TBL] [Abstract][Full Text] [Related]
20. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Frasci G; Nicolella G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Natale M; Piantedosi F; Russo A; Palmeri S; Comella G; Panza N Br J Cancer; 2001 May; 84(9):1166-71. PubMed ID: 11336465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]